Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Service firm Avara buys AstraZeneca plant
by Michael McCoy
September 19, 2016
| A version of this story appeared in
Volume 94, Issue 37
One-year-old Avara Pharmaceutical Services is continuing its rapid growth with the purchase of AstraZeneca’s active pharmaceutical ingredient (API) plant in Avonmouth, England. The facility, which employs about 210 people, mainly makes the APIs in the drugs Crestor and Seroquel. Drug industry veteran Tim Tyson launched Avara in 2015 with the purchase of a Merck & Co. formulation plant in Arecibo, P.R. Earlier this year, the firm acquired a UCB API plant in Shannon, Ireland. And last month, it acquired an Astellas Pharma drug formulation and packaging plant in Norman, Okla.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X